Plasma Calcitonin Gene-Related Peptide (CGRP) Levels in Patients With Head and Neck Malignancies Undergoing Radiotherapy

Summary

This prospective study investigates the dynamic changes in plasma calcitonin gene-related peptide (CGRP) levels during radiotherapy and their association with radiotherapy-related pain in patients with head and neck malignancies.

Eligibility

Inclusion Criteria:

* Age ≥ 18 years

Histologically confirmed head and neck malignancy

Planned to receive definitive or postoperative adjuvant radiotherapy

Radiotherapy duration ≥ 4 weeks, with irradiation field involving the oral cavity, pharynx, or neck region

Able and willing to provide written informed consent

Able to complete pain assessments and blood sample collection

Exclusion Criteria:

* History of significant chronic pain prior to radiotherapy (e.g., postherpetic neuralgia, rheumatoid arthritis)

Presence of uncontrolled hypertension, diabetes, or migraines

Presence of other active malignancies or major systemic diseases (e.g., severe hepatic or renal dysfunction)

Currently receiving or recently received treatments that may significantly affect pain perception (e.g., opioids, antidepressants)

Pregnant or breastfeeding

Inability to complete follow-up or poor treatment compliance

Conditions2

Browse More Trials